Simultaneous development of two cases of eosinophilia-myalgia syndrome with the same lot of L-tryptophan in Japan.
A newly recognized and well-described connective tissue disease, eosinophilia-myalgia syndrome, is thought to relate to L-tryptophan ingestion. The suspect L-tryptophan made in Japan has been distributed in Japan and in the United States. Different from many case reports of eosinophilia-myalgia syndrome in the United States, it has not been reported in Japan. We describe the first case reports of two Japanese patients. Eosinophilia-myalgia syndrome developed in these patients simultaneously, during L-tryptophan treatment by the same physician using the same lot of prescribed L-tryptophan. Furthermore, both patients had the following HLA types: HLA-Aw33(w19), -B44(12), and -DR6. These findings implicate the existence of another factor in the development of eosinophilia-myalgia syndrome in addition to the suspect L-tryptophan.
Mizutani
T
T
Department of Dermatology, Mie University, School of Medicine, Japan.
Mizutani
H
H
Hashimoto
K
K
Nakamura
Y
Y
Kishida
M
M
Taniguchi
H
H
Murata
M
M
Kuzuhara
S
S
Shimizu
M
M
D000368:Aged; D016603:Eosinophilia-Myalgia Syndrome / Q000139:chemically induced / Q000150:complications / Q000473:pathology*; D005260:Female; D006801:Humans; D007564:Japan; D012867:Skin / Q000648:ultrastructure; D012871:Skin Diseases / Q000139:chemically induced / Q000150:complications / Q000473:pathology*; D014364:Tryptophan / Q000009:adverse effects
D014364:Tryptophan